Do I need an in-person exam for Mounjaro in Pennsylvania?

If you’ve been researching weight loss options, you’ve likely encountered medications like Wegovy, Ozempic, or Mounjaro—powerful GLP-1 receptor agonists that have transformed obesity treatment. But with busy schedules and limited access to specialists, many people wonder: Can I get these medications through telehealth?

The short answer is yes—and for most Americans, it’s entirely legal and safe. This comprehensive guide will walk you through everything you need to know about accessing weight loss medications online, including federal and state regulations, what to expect from a telehealth visit, and how to ensure you’re working with a legitimate provider.

Understanding Telehealth for Weight Loss: The Legal Landscape

Federal Law: No In-Person Requirement for GLP-1 Medications

Here’s the most important fact: GLP-1 medications like Wegovy, Ozempic, and Mounjaro are not controlled substances under federal law. This means the Ryan Haight Act—which typically requires an in-person exam before prescribing certain medications—doesn’t apply to these weight loss drugs.

Unlike stimulant medications (such as phentermine or Adderall), which are classified as controlled substances, GLP-1 agonists can be legally prescribed via telehealth without an initial in-person visit under federal regulations. This distinction is crucial and often misunderstood.

During the COVID-19 pandemic, the Drug Enforcement Administration (DEA) relaxed prescribing rules for controlled substances through emergency flexibilities. These temporary measures have been extended through December 31, 2025, but they primarily affect medications like ADHD treatments or opioid addiction therapy—not weight loss medications, which were already accessible via telehealth.

Bottom line: From a federal perspective, a licensed healthcare provider can evaluate you through a video consultation and electronically send a prescription for Wegovy, Ozempic, or Mounjaro to your pharmacy if you medically qualify.

State Variations: What You Need to Know

While federal law permits telehealth prescribing of GLP-1 medications, individual states add their own requirements. The rules vary significantly depending on where you live.

States with minimal restrictions (like California, Washington, New York, and Illinois) allow providers to prescribe weight loss medications entirely through telehealth, with no in-person visit required—ever. The telehealth evaluation itself establishes a valid patient-provider relationship.

States requiring an initial in-person exam (including Arkansas, Georgia, Delaware, South Carolina, and Texas) mandate that patients complete at least one face-to-face visit with a healthcare provider before or shortly after starting telehealth weight loss treatment. This initial exam typically includes a physical assessment, vital signs, and potentially lab work.

States with ongoing monitoring requirements (such as Florida and Virginia) not only require thorough initial evaluations but also mandate regular follow-up appointments. For example, Florida law requires patients receiving obesity medications to have at least one follow-up visit every three months during treatment.

The good news? No state outright bans telehealth for weight loss medications. The differences are about meeting specific standards of care, not preventing access altogether.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Who Can Prescribe Weight Loss Medications via Telehealth?

Physicians, Nurse Practitioners, and Physician Assistants

All 50 states allow licensed physicians (MDs and DOs) to prescribe GLP-1 medications through telehealth, provided they hold an active medical license in the state where the patient is located.

Nurse Practitioners (NPs) and Physician Assistants (PAs) can also prescribe these medications, though their level of independence varies by state:

Full Practice Authority States (34 states plus DC as of 2025): NPs can prescribe independently without physician oversight. Examples include Washington, Arizona, New York, California, Connecticut, and Utah. In these states, you might receive your entire weight loss care from an NP through a telehealth platform.

Reduced Practice Authority States: NPs can prescribe but must work under a collaborative agreement with a supervising physician. This includes states like Florida, Georgia, Illinois, and Pennsylvania. The practical impact for patients is minimal—you’ll still receive quality care, but an NP will have a physician available for consultation.

Restricted Practice States (very few): Some states maintain more oversight of NP prescribing, particularly for certain medication classes. Texas, for instance, requires NPs to have formal delegation agreements with physicians, though GLP-1 medications remain accessible through this model.

Recent legislative trends strongly favor expanding NP autonomy. Georgia passed legislation in 2024 allowing NPs and PAs to prescribe Schedule II controlled substances with physician delegation—a significant expansion of prescriptive authority that signals growing trust in advanced practice providers.

What this means for you: Whether you see an MD, DO, NP, or PA through telehealth, you can feel confident in their qualifications. Legitimate telehealth platforms like Klarity Health carefully credential all providers and ensure they’re operating within their state’s scope of practice.

How Telehealth Weight Loss Programs Work

The Initial Consultation Process

Getting started with a telehealth weight loss program typically follows these steps:

1. Complete a comprehensive medical questionnaire. Expect detailed questions about your medical history, current medications, allergies, previous weight loss attempts, mental health conditions, and family history (particularly regarding thyroid cancer or multiple endocrine neoplasia, which are contraindications for GLP-1 therapy).

2. Provide current measurements. You’ll need to submit your height, current weight, and calculate your BMI. Some platforms require photo verification or ask you to weigh yourself during the video visit.

3. Schedule a live video consultation. Most states require synchronous (real-time) video communication to establish a valid telehealth relationship. Audio-only phone calls generally don’t meet the standard for prescribing.

4. Discuss your treatment goals and options. During the video visit, your provider will review your health information, assess your eligibility for medication, discuss potential side effects, and create a personalized treatment plan that includes lifestyle modifications alongside medication.

5. Lab work (if required). Depending on your state and medical history, your provider may order baseline laboratory tests—typically a comprehensive metabolic panel, thyroid function tests, and hemoglobin A1C. Some states mandate these tests before prescribing weight loss medications.

6. Prescription and follow-up. If approved, your provider will electronically send your prescription to a pharmacy of your choice. Most programs schedule follow-up appointments within 2-4 weeks initially, then monthly or quarterly as treatment progresses.

What Makes You Eligible?

Reputable telehealth providers follow FDA guidelines and clinical best practices when determining eligibility. You’ll generally qualify for GLP-1 weight loss medications if you meet these criteria:

BMI Requirements:

• BMI ≥30 (clinical obesity), OR
• BMI ≥27 with at least one weight-related health condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea

Additional Factors:

• Age 18 or older (some medications approved for ages 12+, but telehealth typically serves adults)
• Commitment to lifestyle changes including nutrition and exercise
• No contraindications (see below)

You will NOT qualify if you have:

• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)—all GLP-1 medications carry an FDA boxed warning about these conditions
• Current pregnancy or planning to become pregnant (must discontinue GLP-1s at least 2 months before conception)
• History of severe pancreatitis
• Active gallbladder disease or history of gallstones (relative contraindication)
• Severe gastroparesis or gastrointestinal disorders
• End-stage kidney disease (some medications require dose adjustment)
• History of eating disorders without appropriate mental health support

Providers will also carefully review your current medications. GLP-1s can interact with certain drugs—particularly insulin or sulfonylureas (which may increase hypoglycemia risk)—and dose adjustments may be necessary.

Medication Options Available Through Telehealth

Wegovy (semaglutide 2.4mg) is FDA-approved specifically for chronic weight management. It’s administered as a once-weekly injection that you give yourself at home. Clinical trials showed average weight loss of 15-20% of body weight over 68 weeks when combined with lifestyle interventions.

Ozempic (semaglutide 0.5-1mg) is FDA-approved for type 2 diabetes but frequently prescribed off-label for weight loss. It uses the same active ingredient as Wegovy but at a lower maximum dose. Providers must document the off-label use and obtain informed consent when prescribing for weight management in patients without diabetes.

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Its higher-dose formulation, Zepbound, received FDA approval for chronic weight management in late 2023. Tirzepatide works on both GLP-1 and GIP receptors, potentially leading to greater weight loss than semaglutide alone—clinical trials showed average weight loss of 20-25% of body weight.

All three medications are non-controlled substances, meaning they don’t carry the prescribing restrictions of stimulant diet pills. They require a valid prescription from a licensed provider but don’t involve DEA registration or prescription monitoring programs.

State-by-State Telehealth Requirements

Understanding your state’s specific rules helps set proper expectations. Here’s what patients need to know in states with unique requirements:

States Requiring Initial In-Person Exams

Arkansas maintains some of the strictest telehealth regulations in the country. An initial in-person encounter is required before weight loss medications can be prescribed, though proposals to ease these restrictions were under review in late 2025.

Georgia requires an initial face-to-face physical exam before prescribing obesity medications via telehealth. However, Georgia recently expanded NP/PA prescriptive authority, making it easier to access care once the initial visit is complete.

Delaware and North Dakota both expect an initial hands-on evaluation for weight management treatment, after which ongoing telehealth follow-ups are permitted.

South Carolina mandates an initial in-person visit and periodic in-office evaluations throughout treatment. NPs and PAs can prescribe with physician oversight.

Texas generally expects an in-person exam prior to telehealth prescribing, though the specific requirements can vary by provider type. Texas also requires NPs and PAs to work under physician delegation agreements with no full practice authority.

Mississippi requires patients to see a provider in person at least once before starting telehealth weight loss therapy. The state is considering legislation to grant NPs independent practice authority, which could expand access.

States with Special Documentation Requirements

Connecticut requires providers to include behavioral counseling and a detailed diet/exercise plan as part of any obesity treatment—whether delivered in person or via telehealth. This ensures a comprehensive approach beyond medication alone.

Florida imposes specific conditions: patients must have a BMI ≥30, and follow-up visits are required at least every three months during treatment. Providers must document these visits or risk disciplinary action.

New Jersey has particularly strict rules from the State Board of Medical Examiners. An extensive initial evaluation is required, including comprehensive history, physical examination, laboratory tests, psychological screening, and thorough documentation of risks and benefits. Informed consent specific to weight loss therapy is mandatory.

Virginia requires an initial physical exam, baseline laboratory work, and a personalized diet and exercise plan. A follow-up visit must occur within 30 days of starting medication, with ongoing monitoring throughout treatment.

States with Full Telehealth Access

California, Washington, New York, Illinois, and Pennsylvania allow weight loss medications to be prescribed entirely through telehealth without in-person requirements. These states recognize telehealth evaluations as sufficient to establish a valid patient-provider relationship.

Utah recently expanded NP independence (2023) and embraces telehealth broadly, with only an encouraged (not legally required) initial in-person evaluation for weight management.

Even in these more flexible states, quality providers will conduct thorough assessments, require lab work when medically appropriate, and schedule regular follow-ups to monitor progress and side effects.

The Role of Klarity Health in Telehealth Weight Management

Klarity Health exemplifies how telehealth can deliver safe, effective, and accessible weight loss care. Here’s what sets quality telehealth platforms apart:

Provider Availability: Klarity offers appointments with licensed providers—including board-certified physicians and experienced nurse practitioners—often within 24-48 hours. This eliminates the weeks-long waits common with traditional weight loss specialists.

Transparent Pricing: Klarity provides clear, upfront costs for consultations and follow-up visits. Whether you’re using insurance or paying out-of-pocket, you’ll know exactly what to expect before your appointment.

Insurance and Cash Pay Options: Klarity accepts most major insurance plans and also offers affordable self-pay rates for those without coverage or who prefer not to use insurance. This flexibility ensures more people can access evidence-based weight loss treatment.

Comprehensive Care Model: Beyond just prescribing medication, Klarity providers develop personalized treatment plans that include nutritional guidance, exercise recommendations, and behavioral strategies. Regular check-ins help adjust treatment as needed and address any side effects promptly.

State Compliance: Klarity ensures all providers are properly licensed in the states where they see patients and follows each state’s specific telehealth and prescribing requirements. This attention to regulatory compliance protects both patients and providers.

Continuity of Care: Rather than one-time prescription mills, Klarity focuses on ongoing relationships. You’ll work with the same provider (or care team) throughout your weight loss journey, with regular monitoring of progress, lab results, and medication adjustments.

What to Expect During Treatment

Starting GLP-1 Medications

GLP-1 medications require a dose titration (gradual increase) to minimize side effects and allow your body to adjust. Here’s a typical timeline:

Weeks 1-4: Start at the lowest dose (e.g., Wegovy 0.25mg weekly). You’ll inject the medication once per week, on the same day each week, into your abdomen, thigh, or upper arm. Your provider will teach you proper injection technique during your initial visit.

Month 2: Increase to the next dose level if tolerated well. Common early side effects include mild nausea, decreased appetite, and occasional digestive changes. These typically improve after 1-2 weeks at each dose.

Months 3-5: Continue dose escalation every 4 weeks until reaching the target maintenance dose or the highest dose you tolerate comfortably.

Month 6 onward: Maintain on your therapeutic dose. Most patients see progressive weight loss over 6-12 months, with the most dramatic results between months 3-9.

Follow-Up Care

Regular monitoring is essential for safe, effective treatment:

First month: Expect a follow-up visit 2-4 weeks after starting medication to assess tolerance, review any side effects, and provide additional support for lifestyle changes.

Months 2-6: Monthly check-ins (via video or messaging, depending on your state’s requirements and your provider’s recommendations) to monitor weight loss progress, adjust doses, and address concerns.

Long-term: Quarterly visits once you’ve reached a stable maintenance dose. Your provider may order periodic lab work (every 6-12 months) to check metabolic markers, kidney function, and other health indicators.

Managing Side Effects

The most common side effects of GLP-1 medications are gastrointestinal:

Nausea (the most frequent complaint): Usually mild and improves with time. Eating smaller, more frequent meals and avoiding high-fat foods can help. Anti-nausea medications are available if needed.

Diarrhea or constipation: Staying well-hydrated, eating adequate fiber, and maintaining regular meal times typically helps. Your provider can recommend specific strategies or medications if symptoms persist.

Decreased appetite: This is actually part of how the medication works, but some patients find it initially unsettling. Your provider will help ensure you’re still meeting basic nutritional needs.

Rare but serious side effects require immediate medical attention: severe abdominal pain (possible pancreatitis), persistent vomiting, vision changes, signs of gallbladder problems, or symptoms of thyroid tumors (lump in neck, hoarseness, difficulty swallowing). Contact your provider immediately if you experience any of these.

Quality telehealth programs make it easy to reach your care team between scheduled visits if you have concerns or experience unexpected symptoms.

Red Flags: How to Avoid Telehealth Scams

The popularity of GLP-1 medications has unfortunately attracted some unscrupulous operators. Protect yourself by watching for these warning signs:

Guaranteed Prescriptions

Red flag: Any service that guarantees you’ll receive a prescription before completing a medical evaluation.

What’s legitimate: Reputable providers assess your eligibility and may determine that medication isn’t appropriate for you. They’ll explain alternatives or reasons for the decision.

Compounded or ‘Generic’ Versions

Red flag: Offers of compounded semaglutide or tirzepatide, overseas versions, or suspiciously cheap ‘generic Wegovy.’

What’s legitimate: As of May 2025, the FDA banned routine compounding of semaglutide for weight loss due to safety concerns. Legitimate providers prescribe FDA-approved brand-name medications: Wegovy, Ozempic, Mounjaro, or Zepbound. While these medications are expensive, there are no legal generic alternatives yet.

No Follow-Up or Monitoring

Red flag: Services that send you months of medication with no scheduled follow-ups or ongoing monitoring.

What’s legitimate: Evidence-based weight loss care includes regular check-ins, dose adjustments, side effect management, and periodic lab work. Your provider should want to see you regularly.

Unclear Provider Credentials

Red flag: Not knowing who will prescribe your medication, unclear licensing information, or providers licensed in different states than where you live.

What’s legitimate: You should know your provider’s name, credentials (MD, DO, NP, PA), and confirm they’re licensed in your state. Klarity Health and other reputable platforms prominently display provider information and ensure proper state licensure.

Skipping Informed Consent

Red flag: No discussion of risks, side effects, contraindications, or alternatives to medication.

What’s legitimate: Your provider should thoroughly review potential side effects, who shouldn’t take these medications, the importance of lifestyle changes, and answer all your questions before prescribing.

No Physical Address or Contact Information

Red flag: Websites without clear contact information, physical addresses, or ways to reach support between appointments.

What’s legitimate: Established telehealth companies have transparent contact information, customer support, and clear policies about privacy and data security.

Cost Considerations and Insurance Coverage

Insurance Coverage for Telehealth Weight Loss

Insurance coverage for GLP-1 weight loss medications varies significantly:

Medicare: As of 2025, traditional Medicare Part D does not cover weight loss medications, though coverage for obesity counseling via telehealth was extended. Medicare Advantage plans may offer some coverage—check your specific plan.

Commercial Insurance: Coverage depends on your specific plan. Some insurers cover Wegovy or Zepbound for obesity when medical criteria are met (documented BMI ≥30 or ≥27 with comorbidities, previous weight loss attempts, etc.). Prior authorization is typically required.

Medicaid: Coverage varies by state. Some state Medicaid programs cover obesity medications; others don’t.

Telehealth Visit Coverage: Most insurance plans now cover telehealth visits at the same rate as in-person appointments, thanks to pandemic-era policy changes that have largely been made permanent.

Out-of-Pocket Costs

Without insurance coverage, expect these approximate costs:

Medication (retail price):

• Wegovy: $1,300-$1,600 per month
• Ozempic: $900-$1,000 per month
• Mounjaro/Zepbound: $1,000-$1,200 per month

Savings Programs: Manufacturer savings cards can reduce costs significantly for eligible patients (typically those with commercial insurance or paying cash—not available for Medicare/Medicaid).

Telehealth Consultation Fees:

• Initial visit: $99-$299 (varies by platform)
• Follow-up visits: $49-$149

Klarity Health offers both insurance billing and transparent cash-pay pricing, often making care more affordable than traditional in-office weight loss programs that may include program fees, counseling charges, and mandatory supplements.

The Future of Telehealth Weight Loss Care

Regulatory Trends to Watch

Federal Telehealth Legislation: The TREATS Act, reintroduced in October 2025, aims to permanently expand telehealth prescribing flexibilities. While focused on addiction treatment and mental health, its passage would signal Congressional support for broader telemedicine access.

DEA Rules: The current telehealth extension for controlled substances expires December 31, 2025. A fourth extension or new permanent rule is expected but not yet finalized. This primarily affects ADHD and addiction medications, not GLP-1s, but indicates the direction of federal telehealth policy.

State Expansions: More states are considering legislation to grant nurse practitioners full practice authority and streamline telehealth requirements. Mississippi, Pennsylvania, and several other states have pending bills that could expand access in 2026.

FDA Oversight: Following the 2025 ban on compounded semaglutide, the FDA continues to monitor telehealth prescribing practices. Expect continued scrutiny to ensure patient safety, but no indication of restrictions on legitimate prescribed medications.

Emerging Treatment Options

New obesity medications are in development, including oral GLP-1 formulations that would eliminate the need for injections. These will likely be available through telehealth platforms as they receive FDA approval.

Combination therapies (GLP-1 plus other mechanisms) are showing promising results in clinical trials, potentially offering even greater weight loss than current single-agent therapies.

Telehealth platforms are also expanding comprehensive services—integrating registered dietitians, health coaches, mental health support, and digital health tools (like continuous glucose monitors or smart scales) to provide truly holistic weight management programs.

Taking the Next Step: Is Telehealth Weight Loss Right for You?

Telehealth offers a convenient, effective, and increasingly accessible path to evidence-based weight loss treatment. It’s particularly valuable if you:

• Live in an area with limited access to weight loss specialists
• Have a busy schedule that makes regular in-office visits challenging
• Prefer the privacy and comfort of receiving care from home
• Want access to the latest FDA-approved obesity medications
• Are looking for comprehensive care that addresses nutrition, activity, and behavior alongside medication

Before starting a telehealth weight loss program, consider:

1. Your commitment level: GLP-1 medications work best when combined with lifestyle changes. Are you ready to modify your eating habits and increase physical activity?

2. Your state’s requirements: Check whether your state requires an initial in-person visit or has other specific regulations.

3. Insurance coverage: Understand what your insurance will cover (if applicable) and what your out-of-pocket costs might be.

4. Your medical history: Review contraindications and discuss any concerns with your provider during the initial consultation.

5. Long-term plan: Weight loss medications often require extended treatment (12+ months). Consider the financial and time commitment for ongoing care.

Conclusion: Accessible, Evidence-Based Weight Loss Care

The short answer to ‘Can you get weight loss medication through telehealth?’ is a resounding yes. Thanks to modern regulations, improved technology, and expanded provider networks, millions of Americans now have access to the same FDA-approved obesity medications that were once only available through specialist referrals and months-long waits.

Telehealth has democratized weight loss care—making it more accessible, affordable, and convenient while maintaining rigorous clinical standards. Whether you’re prescribed Wegovy, Ozempic, or Mounjaro through a platform like Klarity Health, you can expect comprehensive evaluations, ongoing monitoring, lifestyle support, and evidence-based treatment.

The key is working with legitimate, licensed providers who follow state and federal regulations, prioritize patient safety, and offer genuine medical care—not just quick prescriptions. When you choose a reputable telehealth platform, you’re not taking shortcuts; you’re accessing the same quality care you’d receive in a traditional medical office, just with added convenience and often better availability.

Ready to explore whether telehealth weight loss treatment is right for you? Klarity Health offers consultations with experienced, licensed providers who can assess your eligibility, answer your questions, and create a personalized treatment plan. With transparent pricing, insurance acceptance, and same-week appointment availability, getting started has never been easier.

Take the first step toward sustainable weight loss with the convenience and support of telehealth—because effective care shouldn’t require sacrificing your schedule, privacy, or peace of mind.

Frequently Asked Questions

Do I need to see a doctor in person before getting weight loss medication online?

It depends on your state. Federal law does not require an in-person visit for GLP-1 medications like Wegovy or Ozempic since they’re not controlled substances. However, states like Arkansas, Georgia, Texas, and South Carolina do require an initial in-person physical exam. Other states like California, Washington, and New York allow the entire treatment process via telehealth. Check the state-specific requirements in our comprehensive table above.

Can nurse practitioners prescribe weight loss medications through telehealth?

Yes, nurse practitioners can prescribe GLP-1 medications in all states, though the level of oversight varies. In states with full practice authority (like Washington, California, New York, and Arizona), NPs can prescribe independently. In other states, they must work under a collaborative agreement with a physician. Either way, you can receive quality care from an NP through telehealth platforms.

Is it safe to get weight loss medication without meeting my doctor face-to-face?

Yes, when done properly. Reputable telehealth providers conduct thorough video consultations, review detailed medical histories, may require lab work, and schedule regular follow-ups—the same standard of care you’d receive in person. The key is choosing a legitimate platform with licensed providers who follow evidence-based protocols, like Klarity Health.

Will my insurance cover telehealth visits for weight loss medication?

Most insurance plans now cover telehealth visits at the same rate as in-person appointments. However, coverage for the medications themselves varies significantly. Some commercial plans cover Wegovy or Zepbound with prior authorization, while traditional Medicare Part D does not cover weight loss medications. Check with your specific plan or ask your telehealth provider about insurance verification services.

What’s the difference between getting Ozempic vs. Wegovy through telehealth?

Wegovy is FDA-approved specifically for chronic weight management, while Ozempic is approved for type 2 diabetes but often prescribed off-label for weight loss. Both contain semaglutide but at different maximum doses. When prescribing Ozempic for weight loss, providers must document the off-label use and obtain informed consent. Either can be prescribed through telehealth in most states.

How do I know if a telehealth weight loss service is legitimate?

Look for these signs: licensed providers whose credentials you can verify, no guaranteed prescriptions before evaluation, FDA-approved medications (not compounded versions), clear follow-up and monitoring plans, transparent pricing, and proper informed consent about risks and side effects. Avoid services offering compounded semaglutide, guaranteed approvals, or no ongoing medical supervision.

📅 RESEARCH CURRENCY STATEMENT
Verified as of: December 17, 2025
Regulatory Status: All federal and state requirements current as of December 2025. DEA telehealth flexibilities remain in effect through December 31, 2025.

Citations

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – Official DEA announcement (November 15, 2024)
   www.dea.gov

2. COVID-era telehealth prescribing extended – Axios News (November 18, 2024)
   www.axios.com

3. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing – McDermott Will & Emery Legal Analysis (November 18, 2024)
   www.mwe.com

4. The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs – Goodwin Procter Client Alert (March 27, 2024)
   www.goodwinlaw.com

5. Know Your State’s Laws Around Semaglutide – Nextech Healthcare Blog (April 11, 2025)
   www.nextech.com

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid